Oncolys BioPharma, Inc. (4588) AI Stock Analysis

• Market Cap: ¥83.49B
• Dividend Yield: N/A
• Average Volume (3M): 1.52M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.11
• Revenue Growth: -9.04%
• EPS Growth: 13.09%
• Country: JP
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -15.37
• Shares Outstanding: 29,291,700
• 10 Day Avg. Volume: 2,742,450
• 30 Day Avg. Volume: 1,517,566
• PEG Ratio: -4.72
• Price to Book (P/B): 8.90
• Price to Sales (P/S): 1247.26
• P/FCF Ratio: -18.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: ¥2,918.00 ▲(206.19% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is held down primarily by weak financial performance—collapsed revenue, persistent large losses, and heavy cash burn—despite a relatively manageable balance sheet. Strong technical momentum lifts the score, while valuation remains constrained by loss-making economics and no dividend support.

Positive Factors

Manageable leverage and larger equity base

An improved debt-to-equity (~0.12) and materially larger equity/assets base provide tangible balance-sheet capacity to fund ongoing R&D and clinical programs. Lower leverage reduces interest burden and preserves strategic optionality versus highly leveraged peers, supporting multi‑quarter runway.

Positive gross profit in recent years

Sustained positive gross margins — including near 100% of revenue in 2024 — indicate the company’s core revenue streams have inherently favorable unit economics. If operating costs are rationalized or revenues scale, these margins support a path to durable operating leverage and eventual profitability.

Specialized pipeline in oncolytic virus therapies

A clear strategic focus on oncolytic virus therapies and novel modalities gives the company a differentiated scientific niche. Specialized expertise and a targeted pipeline can create durable competitive advantage if clinical progress converts to differentiated assets or partnership opportunities over multiple quarters.

Negative Factors

Collapsed revenue trend

A multi-year collapse in revenue sharply reduces scale and undermines core business viability. Declining top line constrains ability to cover fixed R&D and SG&A, removes economies of scale, and makes the business more dependent on financing or material strategic shifts to restore sustainable growth.

Chronic negative operating and free cash flow

Persistent large operating and free cash outflows deplete resources and force reliance on external capital. Over time, heavy cash burn reduces flexibility to invest selectively, raises dilution risk, and constrains long-term R&D planning unless a clear inflection in revenue or financing strategy emerges.

Consistently large operating and net losses

Sustained substantial operating and net losses imply structural unprofitability absent a major revenue inflection or cost transformation. Continued negative returns on equity heighten the risk of balance-sheet erosion and future dilution, limiting the company's ability to self-fund long‑term clinical development.

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma Inc. engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States. Its product pipeline includes Telomelysin (OBP-301), an oncolytic adenovirus that is in phase II clinical trial for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers; and in phase I clinical trial for the treatment of hepatocellular carcinoma. The company's product pipeline also includes OBP-702, a telomerase-specific oncolytic adenovirus, which is in pre-clinical trial for the treatment of solid tumors; OBP-2011, which is in pre-clinical trial for the treatment of SARS-Cov-2 virus infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed the phase IIb clinical trial for the treatment of HIV infection; and OBP-801, a histone deacetylase inhibitor, which is in phase I clinical trial for the treatment of solid tumors, as well as in pre-clinical trial for ophthalmic use. In addition, it develops TelomeScan (OBP-401 and OBP-1101), a cancer detection drug, for detecting living circulating tumor cells in blood from cancer patients. Further, the company provides diagnostic drugs and inspection services. It has various licensing agreements with Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Oncolys BioPharma Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Oncolys BioPharma generates revenue primarily through the development and commercialization of its proprietary therapeutic products. This includes potential sales of its drugs post-approval, licensing agreements with larger pharmaceutical companies, and collaborations for joint development projects. The company may also receive milestone payments from partners as certain development and regulatory objectives are achieved. Significant partnerships with other biopharmaceutical firms can enhance its revenue streams, providing funding and shared resources for research and development efforts.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Financials are weak overall: revenue has fallen sharply from 2022 levels and remains very low, while operating and net losses are large and persistent. Cash flow is a major risk with heavy, recurring operating cash outflows and negative free cash flow, implying reliance on external financing. The main offset is a comparatively manageable balance sheet with modest leverage and higher equity/assets, providing some flexibility despite ongoing loss-driven erosion risk.

Income Statement

Revenue has collapsed from 976.2M (2022) to 63.0M (2023), 31.4M (2024), and 28.5M (2025), with negative growth in 2023 and 2024 and flat growth in 2025. Profitability is consistently weak: the company reports large operating losses each year (EBIT roughly -1.2B to -2.0B), and net income remains deeply negative across the period. While gross profit is positive in recent years (and even ~100% of revenue in 2024), the scale of operating expenses overwhelms revenue, leaving no visible path to near-term earnings without a major revenue inflection or cost reset.

Balance Sheet

Leverage appears manageable: debt is relatively modest versus equity (debt-to-equity improved to ~0.12 in 2024 from ~0.21 in 2023). The balance sheet expanded meaningfully, with equity rising to ~4.0B and assets to ~4.6B in 2025, suggesting funding support and balance-sheet capacity. The key weakness is ongoing value erosion risk from persistent losses, reflected in consistently negative returns on equity in the available annual data (2020–2024), which could pressure equity over time if losses continue.

Cash Flow

Cash generation is consistently negative: operating cash flow is materially outflowing every year (about -1.3B to -2.0B), and free cash flow is similarly negative, indicating the business is not self-funding. Free cash flow worsened in 2024 versus 2023, and the cash burn remains heavy in 2025. A partial positive is that free cash flow broadly tracks net losses (close to 1x in 2020–2024), implying limited non-cash distortion—but the underlying burn rate remains the central concern and likely necessitates ongoing external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	28.55M	28.55M	31.38M	63.04M	976.18M	642.49M
Gross Profit	27.68M	28.30M	31.38M	30.61M	338.49M	198.80M
EBITDA	-2.18B	-2.05B	-1.68B	-1.93B	-1.14B	-1.60B
Net Income	-2.24B	-2.06B	-1.68B	-1.94B	-1.15B	-1.62B
Balance Sheet
Total Assets	1.93B	4.56B	3.20B	2.04B	2.65B	4.29B
Cash, Cash Equivalents and Short-Term Investments	1.39B	3.72B	2.41B	1.53B	1.71B	3.45B
Total Debt	377.04M	320.02M	324.64M	315.17M	393.66M	503.47M
Total Liabilities	493.35M	555.91M	446.65M	566.50M	491.69M	697.88M
Stockholders Equity	1.44B	4.00B	2.75B	1.47B	2.16B	3.59B
Cash Flow
Free Cash Flow	0.00	-1.94B	-2.02B	-1.34B	-1.72B	-1.74B
Operating Cash Flow	0.00	-1.94B	-2.02B	-1.34B	-1.72B	-1.74B
Investing Cash Flow	0.00	-7.58M	-4.71M	-5.39M	20.12M	-942.00K
Financing Cash Flow	0.00	3.22B	2.88B	1.14B	-113.83M	3.09B

Oncolys BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 953.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 953 is below the 20-day moving average (MA) of 2210.55, below the 50-day MA of 1778.44, and below the 200-day MA of 976.66, indicating a bullish trend. The MACD of 239.77 indicates Negative momentum. The RSI at 69.87 is Neutral, neither overbought nor oversold. The STOCH value of 82.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4588	55 Neutral	¥83.49B	-35.68	―	―	-9.04%	13.09%
4974	52 Neutral	¥138.12B	-19.18	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4575	51 Neutral	¥16.62B	-13.14	―	―	―	14.03%
4583	47 Neutral	¥7.73B	-7.53	―	―	25.28%	39.15%
4587	46 Neutral	¥185.72B	-49.34	-10.16%	―	-62.47%	-134.06%
4564	42 Neutral	¥8.06B	-7.29	-63.25%	―	99.87%	40.60%